Approval · Notice of Compliance 19653 · 2017
PRIORIX: Notice of Compliance 19653
Issued August 11, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19653
- Date
- August 11, 2017
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Labelling updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRIORIX | Not yet assigned | — |
Medicinal ingredients
- MEASLES VIRUS VACCINE LIVE ATTENUATED 1,000 UNIT per 0.5ML
- WATER 0.5 ML per 0.5ML
- MUMPS VIRUS VACCINE LIVE ATTENUATED JERYL LYNN STRAIN 10,000 UNIT per 0.5ML
- RUBELLA VIRUS VACCINE LIVE ATTENUATED WISTAR RA27/3 STRAIN 1,000 UNIT per 0.5ML